252 related articles for article (PubMed ID: 33114676)
1. Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19.
Brábek J; Jakubek M; Vellieux F; Novotný J; Kolář M; Lacina L; Szabo P; Strnadová K; Rösel D; Dvořánková B; Smetana K
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114676
[TBL] [Abstract][Full Text] [Related]
2. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.
Crisafulli S; Isgrò V; La Corte L; Atzeni F; Trifirò G
BioDrugs; 2020 Aug; 34(4):415-422. PubMed ID: 32557214
[TBL] [Abstract][Full Text] [Related]
3. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052
[TBL] [Abstract][Full Text] [Related]
4. Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.
Palanques-Pastor T; López-Briz E; Poveda Andrés JL
Eur J Hosp Pharm; 2020 Sep; 27(5):297-298. PubMed ID: 32499314
[TBL] [Abstract][Full Text] [Related]
5. IL-4/IL-13 remodeling pathway of COVID-19 lung injury.
Vaz de Paula CB; de Azevedo MLV; Nagashima S; Martins APC; Malaquias MAS; Miggiolaro AFRDS; da Silva Motta Júnior J; Avelino G; do Carmo LAP; Carstens LB; de Noronha L
Sci Rep; 2020 Oct; 10(1):18689. PubMed ID: 33122784
[TBL] [Abstract][Full Text] [Related]
6. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
7. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019.
Chen X; Zhao B; Qu Y; Chen Y; Xiong J; Feng Y; Men D; Huang Q; Liu Y; Yang B; Ding J; Li F
Clin Infect Dis; 2020 Nov; 71(8):1937-1942. PubMed ID: 32301997
[TBL] [Abstract][Full Text] [Related]
8. Cytokine Storm in COVID19: A Neural Hypothesis.
Ur A; Verma K
ACS Chem Neurosci; 2020 Jul; 11(13):1868-1870. PubMed ID: 32605374
[TBL] [Abstract][Full Text] [Related]
9. Fragile Endothelium and Brain Dysregulated Neurochemical Activity in COVID-19.
Alharthy A; Faqihi F; Memish ZA; Karakitsos D
ACS Chem Neurosci; 2020 Aug; 11(15):2159-2162. PubMed ID: 32786343
[TBL] [Abstract][Full Text] [Related]
10. Acute Inflammation and Elevated Cardiac Markers in a Two-Month-Old Infant with Severe Acute Respiratory Syndrome Coronavirus 2 Infection Presenting with Cardiac Symptoms.
Giacomet V; Manfredini VA; Meraviglia G; Peri CF; Sala A; Longoni E; Gasperetti A; Stracuzzi M; Mannarino S; Zuccotti GV
Pediatr Infect Dis J; 2020 Jul; 39(7):e149-e151. PubMed ID: 32433225
[TBL] [Abstract][Full Text] [Related]
11. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China.
Wang Z; Yang B; Li Q; Wen L; Zhang R
Clin Infect Dis; 2020 Jul; 71(15):769-777. PubMed ID: 32176772
[TBL] [Abstract][Full Text] [Related]
12. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.
Hou H; Zhang B; Huang H; Luo Y; Wu S; Tang G; Liu W; Mao L; Mao L; Wang F; Sun Z
Clin Exp Immunol; 2020 Jul; 201(1):76-84. PubMed ID: 32365221
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 and obesity: links and risks.
Lavie CJ; Sanchis-Gomar F; Henry BM; Lippi G
Expert Rev Endocrinol Metab; 2020 Jul; 15(4):215-216. PubMed ID: 32441223
[No Abstract] [Full Text] [Related]
14. Pathological features of COVID-19-associated lung injury: a preliminary proteomics report based on clinical samples.
Leng L; Cao R; Ma J; Mou D; Zhu Y; Li W; Lv L; Gao D; Zhang S; Gong F; Zhao L; Qiu B; Xiang H; Hu Z; Feng Y; Dai Y; Zhao J; Wu Z; Li H; Zhong W
Signal Transduct Target Ther; 2020 Oct; 5(1):240. PubMed ID: 33060566
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19).
Cure E; Kucuk A; Cumhur Cure M
Rheumatol Int; 2020 Jul; 40(7):1177-1179. PubMed ID: 32415310
[No Abstract] [Full Text] [Related]
16. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.
Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G
Front Immunol; 2020; 11():588724. PubMed ID: 33117402
[TBL] [Abstract][Full Text] [Related]
17. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?
Kazama I
Drug Discov Ther; 2020 Jul; 14(3):143-144. PubMed ID: 32581194
[TBL] [Abstract][Full Text] [Related]
18. The Science Underlying COVID-19: Implications for the Cardiovascular System.
Liu PP; Blet A; Smyth D; Li H
Circulation; 2020 Jul; 142(1):68-78. PubMed ID: 32293910
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.
Smetana K; Rosel D; BrÁbek J
In Vivo; 2020; 34(5):3027-3028. PubMed ID: 32871847
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 as a potential biomarker of COVID-19 progression.
Ulhaq ZS; Soraya GV
Med Mal Infect; 2020 Jun; 50(4):382-383. PubMed ID: 32259560
[No Abstract] [Full Text] [Related]
[Next] [New Search]
